The combination of nab-Paclitaxel and Atezolizumab as first line therapy for metastatic triple-negative breast cancer patients with PD-L1 expression ≥1% on immune cells (by SP142 Ventana assay) has been approved by both FDA (Food and Drug Administration) and EMA (European Medicines Agency) based on the positive results of the Impassion130 randomized trial [54]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.